|Bid||14.01 x 900|
|Ask||14.82 x 1400|
|Day's Range||14.65 - 14.94|
|52 Week Range||13.26 - 20.54|
|Beta (3Y Monthly)||0.61|
|PE Ratio (TTM)||4.20|
|Earnings Date||Feb 6, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.00|
Announcement: Moody's announces completion of a periodic review of ratings of Innoviva, Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Innoviva, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Innoviva Inc NASDAQ/NGS:INVAView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for INVA with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding INVA totaled $2.44 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
On a per-share basis, the Brisbane, California-based company said it had profit of $2.34. The biopharmaceutical company posted revenue of $79.9 million in the period. For the year, the company reported ...
BRISBANE, Calif.-- -- Total net revenue rose 15% to $79.9 million in the fourth quarter of 2018 compared with the fourth quarter of 2017. 1 Income before income taxes increased 25% from the fourth quarter of 2017 to $73.1 million. Innoviva, Inc. today reported financial results for the fourth quarter ended December 31, 2018. Gross royalty revenues of $83.3 million from Glaxo Group Limited for the fourth ...
NEW YORK, Feb. 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Mylan stock popped late Wednesday after the Food and Drug Administration approved its generic version of GlaxoSmithKline asthma inhaler Advair. Mylan shares rose 7%.
Innoviva, Inc. (NASDAQ:INVA) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In the case Read More...
The Dow Jones industrial average and other key averages still show strength in 2019 after the big slide in Q4 last year. Market technicals are improving.
Innoviva is among a select group of stocks to watch in the biotech sector thanks to strong fundamentals and a bullish chart.
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in October, blaming macroeconomic conditions and unpredictable events that hit several sectors, with healthcare among them. Nevertheless, most investors decided to stick to their bullish theses and their long-term focus allows us to profit from the recent declines. […]
Innoviva (INVA) stock is looking quite impressive for momentum-oriented investors as it has favorable price performance and is also seeing positive estimate revisions.
Stocks pared losses as the market started the final hour of a shortened session Friday, while some consumer stocks led at the start of the holiday shopping season.
Innoviva is the IBD Stock Of The Day as the biotech stock flirts with a breakout amid new uses for its GlaxoSmithKline-partnered medicines. Innoviva has several royalty deals with Glaxo.
Glaxo (GSK) and Innoviva announce approval of label expansion for COPD drug, Trelegy Ellipta, in Europe to include patients not adequately treated with dual bronchodilation.
Innoviva, Inc. (INVA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front